The "Oncology Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.
Oncology Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030 provides the strategists, marketers and senior management with the critical information they need to assess the global oncology drugs market as it emerges from the COVID-19 shut down.
Major companies in the oncology drugs market include F. Hoffmann-La Roche Ltd; Novartis AG; Gilead Sciences Inc; Bayer AG and Takeda Pharmaceticals.
The global oncology drugs market is expected to grow from $80.92 billion in 2020 to $84.38 billion in 2021 at a compound annual growth rate (CAGR) of 4.3%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $112.14 billion in 2025 at a CAGR of 7%.
The oncology drugs market consists of sales of oncology drugs and related services by entities (organizations, sole traders and partnerships) that produce oncology drugs to diagnose and treat all types of cancers.
Companies in the oncology drug market are investing in targeted therapy, which has proven to be less toxic compared to traditional treatment options. Targeted cancer therapies are drugs or substances which block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity. The goal of these therapies is to eliminate cancerous cells in the body while leaving normal cells unharmed.
By focusing on changes in the cell that are specific to cancer, this therapy may prove to be more effective than traditional chemotherapy and radiotherapy. Companies in oncology market such as Pfizer, Novartis and Abbvie have understood the importance of this treatment method and are increasingly investing in it. According to a report by QuintilesIMS, 87% of the drugs currently in pipeline constitute of targeted therapy drugs.
Companies in the oncology drugs market are increasingly investing in technologies such as artificial intelligence (AI) to save time and reduce research and development costs. AI is the simulation of human intelligence processes by machines, especially computer systems, which has the potential to surpass human intelligence levels.
This technology helps to analyze large sets of chemical and biological data to identify potential drug candidates with higher success rates and at a quicker pace when compared to human analysis. The technology also helps in speeding up the patient recruitment process by matching cancer patients with the most relevant clinical trials, thus lowering clinical trial costs.
Major oncology drug manufacturers such as Roche, Pfizer and Johnson and Johnson have already invested in AI technologies to reduce time taken and costs incurred for drug development. For example, Johnson and Johnson has recently entered into an agreement with BenevolentAI, a UK-based start-up, to mine data for designing new oncology drugs.
Key Topics Covered:
1. Executive Summary
2. Report Structure
3. Oncology Drugs Market Characteristics
3.1. Market Definition
3.2. Key Segmentations
4. Oncology Drugs Market Product Analysis
4.1. Leading Products/ Services
4.2. Key Features and Differentiators
4.3. Development Products
5. Oncology Drugs Market Supply Chain
5.1. Supply Chain
5.3. End Customers
6. Oncology Drugs Market Customer Information
6.1. Customer Preferences
6.2. End Use Market Size and Growth
7. Oncology Drugs Market Trends and Strategies
8. Impact of COVID-19 on Oncology Drugs
9. Oncology Drugs Market Size and Growth
9.1. Market Size
9.2. Historic Market Growth, Value ($ Billion)
9.2.1. Drivers of the Market
9.2.2. Restraints on the Market
9.3. Forecast Market Growth, Value ($ Billion)
9.3.1. Drivers of the Market
9.3.2. Restraints on the Market
10. Oncology Drugs Market Regional Analysis
10.1. Global Oncology Drugs Market, 2020, by Region, Value ($ Billion)
10.2. Global Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Region
10.3. Global Oncology Drugs Market, Growth and Market Share Comparison, by Region
11. Oncology Drugs Market Segmentation
11.1. Global Oncology Drugs Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
Lung Cancer Drugs
Pancreatic Cancer Drugs
Breast Cancer Drugs
Prostate Cancer Drugs
Ovarian Cancer Drugs
Colorectal Cancer Drugs
Gastric Cancer Drugs
Kidney Cancer Drugs
Brain Tumor Drugs
Thyroid Cancer Drugs
Skin Cancer Drugs
Bladder Cancer Drugs
Cervical Cancer Drugs
Blood Cancer Drugs
Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)
11.2. Global Oncology Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
Retail Pharmacies/ Drug Stores
11.3. Global Oncology Drugs Market, Segmentation by Route of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11.4. Global Oncology Drugs Market, Segmentation by Drug Classification, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11.5. Global Oncology Drugs Market, Segmentation by Mode of Purchase, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12. Oncology Drugs Market Metrics
12.1. Oncology Drugs Market Size, Percentage of GDP, 2015-2025, Global
12.2. Per Capita Average Oncology Drugs Market Expenditure, 2015-2025, Global
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc
For more information about this report visit https://www.researchandmarkets.com/r/d43il2
View source version on businesswire.com: https://www.businesswire.com/news/home/20210308005632/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900